Ampersand Biomedicines (Series B)
Funding Details
- Awarder
- Inbox
- Date Award
- March 19, 2025
- Vertical
- Pharmaceuticals and Biotechnology
- Funding URL
- View Funding Page
- Funding Amount:
- $65,000,000
Company Info
- Founding Year
- 2021
- Traction
- Two lead programs in immuno-inflammation and immuno-oncology planned to enter IND-enabling studies in 2025. Second discovery partnership in obesity initiated.
- Organizations Involved
- Eli Lilly & Company, Pfizer
- Founders
- Flagship Pioneering
- Company Description
- Ampersand Biomedicines is a multi-product platform that develops programmable medicines that target disease sites precisely.
- Market
- Biologics
- Location
- Boston, Massachusetts, USA
- Coinvestors
- Flagship Pioneering, Eli Lilly & Company